These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 15824729

  • 1. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B.
    Oncogene; 2005 Jul 21; 24(31):4993-9. PubMed ID: 15824729
    [Abstract] [Full Text] [Related]

  • 2. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS.
    Mol Cancer Ther; 2005 Mar 21; 4(3):443-9. PubMed ID: 15767553
    [Abstract] [Full Text] [Related]

  • 3. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, Dong F, Fang B.
    Cancer Biol Ther; 2005 Jul 21; 4(7):781-6. PubMed ID: 16082182
    [Abstract] [Full Text] [Related]

  • 4. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.
    Cancer Res; 2007 Jun 01; 67(11):5418-24. PubMed ID: 17545623
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.
    J Clin Endocrinol Metab; 2006 Oct 01; 91(10):4013-21. PubMed ID: 16849420
    [Abstract] [Full Text] [Related]

  • 6. Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors.
    Zhou W, Hu J, Tang H, Wang D, Huang X, He C, Zhu H.
    BMC Cancer; 2011 Nov 14; 11():485. PubMed ID: 22078414
    [Abstract] [Full Text] [Related]

  • 7. Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
    Teraishi F, Guo W, Zhang L, Dong F, Davis JJ, Sasazuki T, Shirasawa S, Liu J, Fang B.
    Cancer Res; 2006 Jun 15; 66(12):6072-9. PubMed ID: 16778179
    [Abstract] [Full Text] [Related]

  • 8. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Fribley A, Zeng Q, Wang CY.
    Mol Cell Biol; 2004 Nov 15; 24(22):9695-704. PubMed ID: 15509775
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C, Li R, Grandis JR, Johnson DE.
    Mol Cancer Ther; 2008 Jun 15; 7(6):1647-55. PubMed ID: 18566236
    [Abstract] [Full Text] [Related]

  • 10. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.
    Cancer Res; 2007 Feb 15; 67(4):1783-92. PubMed ID: 17308121
    [Abstract] [Full Text] [Related]

  • 11. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 12. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Cognetti F, Humphreys R, Peschle C, Testa U.
    Apoptosis; 2007 Apr 01; 12(4):635-55. PubMed ID: 17252198
    [Abstract] [Full Text] [Related]

  • 13. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.
    Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S.
    Mol Cell Biol; 2014 Sep 15; 34(18):3435-49. PubMed ID: 25002530
    [Abstract] [Full Text] [Related]

  • 14. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 15; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.
    Anticancer Res; 2006 Oct 15; 26(3A):1869-76. PubMed ID: 16827119
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y.
    Acta Haematol; 2006 Oct 15; 115(1-2):78-90. PubMed ID: 16424655
    [Abstract] [Full Text] [Related]

  • 19. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
    An J, Sun Y, Fisher M, Rettig MB.
    Mol Cancer Ther; 2004 Jun 15; 3(6):727-36. PubMed ID: 15210859
    [Abstract] [Full Text] [Related]

  • 20. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.